p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
Silvana Mourón(Spanish National Cancer Research Centre), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), Diego Malón(Hospital Universitario de Fuenlabrada), Manuel Muñoz(Spanish National Cancer Research Centre), Juan Antonio Guerra(Hospital Universitario de Fuenlabrada), Luís Manso(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Raúl Torres(Spanish National Cancer Research Centre), María J. Bueno(Spanish National Cancer Research Centre), Sandra Rodríguez(Spanish National Cancer Research Centre), Laura Rodríguez-Lajusticia(Hospital Universitario de Fuenlabrada), Juan V. Apala(Spanish National Cancer Research Centre), Jorge Silva(University of Lisbon), Marcos Malumbres(Institució Catalana de Recerca i Estudis Avançats)
Cited by 2
Related Papers
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy
|Cell Death and Disease|2013|237
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5
|Molecular Cell|2012|204